<DOC>
	<DOCNO>NCT00006452</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs gadolinium texaphyrin may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness gadolinium texaphyrin plus radiation therapy treat patient supratentorial glioblastoma multiforme previously treat .</brief_summary>
	<brief_title>Gadolinium Texaphyrin Plus Radiation Therapy Treating Patients With Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxic effect gadolinium texaphyrin administer patient receive cranial radiotherapy glioblastoma multiforme . II . Determine maximum tolerate dose regimen patient . III . Determine pharmacokinetic profile regimen patient . IV . Determine biodistribution gadolinium texaphyrin neoplastic tissue normal brain parenchyma . V. Evaluate effect accumulation regimen normal brain parenchyma neoplastic tissue follow change enhance volume percent change signal intensity time . OUTLINE : This open label , multicenter study . Arm I : Patients receive radiotherapy day , 5 day week , 6 week . Gadolinium texaphyrin IV administer every day within 2-5 hour prior radiotherapy . Patients evaluate 1 month , 1 3 patient experience unacceptable toxicity , 3 patient enter image portion study . Once arm I successfully enter 3 patient acceptable toxicity profile 3 patient image portion study , patient enrollment begin arm II . Arm II : Cohorts 3-9 patient receive radiotherapy arm I escalate dos gadolinium texaphyrin IV administer within 2-5 hour prior radiation dose . The maximum tolerated dose ( MTD ) gadolinium texaphyrin define dose one third patient experience dose limit toxicity . Arm III : Patients experience dose limit toxicity arm II require dose reduction predetermine day limit receive gadolinium every day , radiotherapy arm II . The MTD define arm II . Arm IV : An additional 3 patient enrol MTD enter image portion study . Patients follow 1 month final radiation therapy . PROJECTED ACCRUAL : At least 18 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , previously untreated , supratentorial grade IV glioblastoma multiforme Measurable contrast enhance disease postoperative MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 2.0 mg/dL Alkaline phosphatase great 4 time upper limit normal ( ULN ) SGOT SGPT great 4 time ULN PT aPTT normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No serious infection medical illness No history glucose6phosphate dehydrogenase deficiency No know porphyria No prior malignancy within past 5 year except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix breast PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy glioblastoma multiforme No prior immunotoxins , immunoconjugates , antisense , peptide receptor antagonist , interferon , interleukin , tumor infiltrating lymphocyte , lymphokine activate killer cell , gene therapy glioblastoma multiforme Chemotherapy : No prior chemotherapy glioblastoma multiforme Endocrine therapy : No prior hormonal therapy glioblastoma multiforme Stable corticosteroid regimen least 5 day prior study Radiotherapy : No prior radiotherapy glioblastoma multiforme Surgery : Recovered postoperative complication Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>